Cointime update: China’s National Medical Products Administration (NMPA) held a meeting chaired by Director Huang Guo to optimize the management of chemical active pharmaceutical ingredients and the review and approval of cell and gene therapy drugs. The meeting reviewed and approved the Provisions on the Administration of Changes to Registration Holders of Chemical APIs and the Announcement on Matters Concerning the Optimization of Review and Approval of Cell and Gene Therapy Drugs.
China NMPA Moves to Optimize Review of Chemical APIs and Cell & Gene Therapies
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.
Related News
1h ago
Bitwise Files S-1 for Spot Zcash ETF on Texas Stock Exchange
1h ago
House Democrats Target Trump Inner Circle in First Oversight Requests
1h ago
US Democrats Plan Data Center Power Reform, Operators May Pay $35B More Over 10 Years
4h ago
Binance Plans to Enter Five Asian Markets Next Year, Focus on South and Southeast Asia
9h ago
SASAC to Keep SOE Reform Results in Performance Assessment
9h ago
Jiangsu Plans Market-Based Computing Trading, Token Vouchers for AI Compute